Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

NCT04554056 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

586

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Female

Interventions

DRUG: MW05
DRUG: PEG-rhG-CSF

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.